ReviewFrontiers in oncology2023
Determination of short-chain fatty acids as putative biomarkers of cancer diseases by modern analytical strategies and tools: a review.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Current insights and trends in atopic dermatitis and microbiota interactions: a systematic review and bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Microbiome-metabolite signaling networks in gastrointestinal disease: systems biology, network rewiring, and precision therapeutics.Archives of microbiology · 2026Review
- Monitored food intake in early pregnancy modulates the maternal microbiome in the obese BPH/5 mouse model of superimposed preeclampsia.Physiological genomics · 2026Article
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
- Isoflavones impair anti-PD1 efficacy in breast cancer, regardless of dietary fiber or fecal short-chain fatty acid levels.Frontiers in immunology · 2026Article
- Fecal Short-Chain Fatty Acids in Colorectal Cancer Patients Versus Healthy Controls: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Assessment of buffalo and bovine ghee authenticity using fatty acid profile analysis and FTIR spectroscopy.NPJ science of food · 2025Article
- The microbiome in cancer.iMeta · 2025Review
- Metabolomics-Based Diagnosis of Medullary Thyroid Cancer: A Plasma 1H NMR Approach.Iranian journal of public health · 2025Article
- Exploring Innovative Approaches for Managing Spinal Cord Injury: A Comprehensive Review of Promising Probiotics and Postbiotics.Probiotics and antimicrobial proteins · 2025Review
- Blood microbiome signatures in the REM sleep behavior disorder-Lewy body disease continuum.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Metabolomic Prediction of Naphthalene Pneumo-Toxicity in the SnailMetabolites · 2025Article
- Development and Validation of a New LC-MS/MS Method for the Assay of Plasmatic Peripheral Short- and Medium-Chain Fatty Acids for Metabolomics Applications.Metabolites · 2025Article
- Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson's disease.Scientific reports · 2025Article
- Modulation of Gut Microbial Biomarkers and Metabolites in Cancer Management by Tea Compounds.International journal of molecular sciences · 2024Review
- Exploring the microbiome-gut-testis axis in testicular germ cell tumors.Frontiers in cellular and infection microbiology · 2024Review
- Diet-driven microbiome changes and physical activity in cancer patients.Frontiers in nutrition · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Short-chain fatty acids (SCFAs) are the main metabolites produced by bacterial fermentation of non-digestible carbohydrates in the gastrointestinal tract. They can be seen as the major flow of carbon from the diet, through the microbiome to the host. SCFAs have been reported as important molecules responsible for the regulation of intestinal homeostasis. Moreover, these molecules have a significant impact on the immune system and are able to affect inflammation, cardiovascular diseases, diabetes type II, or oncological diseases. For this purpose, SCFAs could be used as putative biomarkers of various diseases, including cancer. A potential diagnostic value may be offered by analyzing SCFAs with the use of advanced analytical approaches such as gas chromatography (GC), liquid chromatography (LC), or capillary electrophoresis (CE) coupled with mass spectrometry (MS). The presented review summarizes the importance of analyzing SCFAs from clinical and analytical perspective. Current advances in the analysis of SCFAs focused on sample pretreatment, separation strategy, and detection methods are highlighted. Additionally, it also shows potential areas for the development of future diagnostic tools in oncology and other varieties of diseases based on targeted metabolite profiling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.